BACKGROUND: The objective of the study was to describe temporal patterns in the management of HIV-1 infected women and their newborns and the changes over time in the mother-to-child transmission (MTCT) rates and risk factors. METHODS: A multicenter prospective observational study was performed in Madrid, Spain, from 2000 to 2007. Cohort period 1 (CP1) included births in 2000-2003 and cohort period 2 (CP2) included births in 2004-2007. RESULTS: Of the 803 HIV-infected women and their infants, 427 were in the CP1 and 376 in CP2. Almost all CP2 women received highly active antiretroviral therapy. More women in CP2 received antiretroviral treatment for ≥16 weeks during pregnancy (72.0% in CP1 vs. 84.8% in CP2; P < 0.001). Overall, no differences in trends in mode of delivery were observed. The proportion of women with vaginal deliveries who had undetectable viral loads increased from 31.1% in CP1 to 42.7% in CP2 (P = 0.02). Thirteen children (1.6%, 95% confidence interval: 0.68-2.55) were HIV-1 infected by MTCT. No changes in the rates of infection were observed over time. All the cases of MTCT occurred when antiretroviral treatment was not given or was given for <16 weeks during pregnancy. CONCLUSIONS: Low MTCT rates were observed over time. Lack of timely provision of antiretroviral drugs was the main limitation to develop all preventive interventions available nowadays. Nonsustained control of viral load could be associated with residual transmission.
BACKGROUND: The objective of the study was to describe temporal patterns in the management of HIV-1 infectedwomen and their newborns and the changes over time in the mother-to-child transmission (MTCT) rates and risk factors. METHODS: A multicenter prospective observational study was performed in Madrid, Spain, from 2000 to 2007. Cohort period 1 (CP1) included births in 2000-2003 and cohort period 2 (CP2) included births in 2004-2007. RESULTS: Of the 803 HIV-infectedwomen and their infants, 427 were in the CP1 and 376 in CP2. Almost all CP2women received highly active antiretroviral therapy. More women in CP2 received antiretroviral treatment for ≥16 weeks during pregnancy (72.0% in CP1 vs. 84.8% in CP2; P < 0.001). Overall, no differences in trends in mode of delivery were observed. The proportion of women with vaginal deliveries who had undetectable viral loads increased from 31.1% in CP1 to 42.7% in CP2 (P = 0.02). Thirteen children (1.6%, 95% confidence interval: 0.68-2.55) were HIV-1 infected by MTCT. No changes in the rates of infection were observed over time. All the cases of MTCT occurred when antiretroviral treatment was not given or was given for <16 weeks during pregnancy. CONCLUSIONS: Low MTCT rates were observed over time. Lack of timely provision of antiretroviral drugs was the main limitation to develop all preventive interventions available nowadays. Nonsustained control of viral load could be associated with residual transmission.
Authors: Ari Bitnun; Terry Lee; Jason Brophy; Lindy M Samson; Fatima Kakkar; Wendy Vaudry; Ben Tan; Deborah M Money; Joel Singer; Laura J Sauvé; Ariane Alimenti Journal: CMAJ Open Date: 2018-05-10
Authors: Luis M Prieto; María Isabel González-Tomé; Eloy Muñoz; María Fernández-Ibieta; Beatriz Soto; Ana Álvarez; Maria Luisa Navarro; Miguel Ángel Roa; José Beceiro; María Isabel de José; Iciar Olabarrieta; David Lora; José Tomás Ramos Journal: BMC Infect Dis Date: 2014-12-24 Impact factor: 3.090
Authors: Luis M Prieto; Carolina Fernández McPhee; Patricia Rojas; Diana Mazariegos; Eloy Muñoz; Maria José Mellado; África Holguín; María Luisa Navarro; María Isabel González-Tomé; José Tomás Ramos Journal: PLoS One Date: 2017-08-25 Impact factor: 3.240
Authors: Maristela Miyamoto; Aída F T B Gouvêa; Erika Ono; Regina Célia M Succi; Savita Pahwa; Maria Isabel de Moraes-Pinto Journal: Rev Inst Med Trop Sao Paulo Date: 2017-06-01 Impact factor: 1.846
Authors: Victoria Hernando; Belen Alejos; Marta Montero; MJesús Pérez-Elias; José Ramón Blanco; Livia Giner; Juan Luis Gómez-Sirvent; Jose Antonio Iribarren; Enrique Bernal; Francisco Bolumar Journal: Medicine (Baltimore) Date: 2017-02 Impact factor: 1.889
Authors: Santiago Jiménez de Ory; José Tomas Ramos; Claudia Fortuny; María Isabel González-Tomé; Maria José Mellado; David Moreno; César Gavilán; Ana Isabel Menasalvas; Ana Isabel Piqueras; M Antoinette Frick; Maria Angeles Muñoz-Fernández; Maria Luisa Navarro Journal: PLoS One Date: 2019-10-24 Impact factor: 3.240
Authors: Sara Domínguez-Rodríguez; Luis Prieto; Carolina Fernández McPhee; Marta Illán-Ramos; José Beceiro; Luis Escosa; Eloy Muñoz; Iciar Olabarrieta; Francisco Javier Regidor; Miguel Ángel Roa; María Del Carmen Viñuela Beneítez; Sara Guillén; Maria Luisa Navarro-Gómez; José Tomás Ramos Amador Journal: PLoS One Date: 2020-04-09 Impact factor: 3.240
Authors: E Bouza; J R Arribas; B Alejos; J I Bernardino; M Coiras; P Coll; J Del Romero; M J Fuster; M Górgolas; A Gutiérrez; D Gracia; V Hernando; J Martínez-Picado; J M Martínez Sesmero; E Martínez; S Moreno; B Mothe; M L Navarro; D Podzamczer; F Pulido; J T Ramos; E Ruiz-Mateos; I Suárez García; E Palomo Journal: Rev Esp Quimioter Date: 2022-01-12 Impact factor: 1.553